Vericel Co. (NASDAQ:VCEL) Shares Sold by Kopp Family Office LLC

Kopp Family Office LLC lessened its stake in Vericel Co. (NASDAQ:VCEL) by 18.5% during the 3rd quarter, according to its most recent 13F filing with the Securities & Exchange Commission. The firm owned 372,948 shares of the biotechnology company’s stock after selling 84,730 shares during the period. Vericel accounts for about 10.2% of Kopp Family Office LLC’s holdings, making the stock its 3rd biggest position. Kopp Family Office LLC owned approximately 0.76% of Vericel worth $15,757,000 as of its most recent filing with the Securities & Exchange Commission.

Several other large investors have also modified their holdings of VCEL. International Assets Investment Management LLC increased its holdings in Vericel by 4,126.7% in the third quarter. International Assets Investment Management LLC now owns 634 shares of the biotechnology company’s stock valued at $27,000 after buying an additional 619 shares in the last quarter. Farther Finance Advisors LLC raised its holdings in shares of Vericel by 48.1% in the third quarter. Farther Finance Advisors LLC now owns 1,247 shares of the biotechnology company’s stock worth $53,000 after acquiring an additional 405 shares during the last quarter. Mirae Asset Global Investments Co. Ltd. lifted its position in shares of Vericel by 22.2% in the third quarter. Mirae Asset Global Investments Co. Ltd. now owns 1,773 shares of the biotechnology company’s stock valued at $77,000 after acquiring an additional 322 shares in the last quarter. Meeder Asset Management Inc. acquired a new stake in shares of Vericel during the third quarter valued at $92,000. Finally, Quantbot Technologies LP purchased a new stake in Vericel during the 3rd quarter worth about $146,000.

Vericel Stock Performance

Shares of Vericel stock traded down $0.62 during midday trading on Tuesday, reaching $54.68. 53,640 shares of the company’s stock traded hands, compared to its average volume of 421,752. The company has a market cap of $2.70 billion, a price-to-earnings ratio of 911.49 and a beta of 1.71. Vericel Co. has a 52 week low of $32.31 and a 52 week high of $61.49. The company’s 50 day simple moving average is $53.61 and its 200 day simple moving average is $48.82.

Vericel (NASDAQ:VCEL) last released its quarterly earnings results on Thursday, November 7th. The biotechnology company reported ($0.02) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.05) by $0.03. The company had revenue of $57.91 million during the quarter, compared to analysts’ expectations of $55.32 million. Vericel had a net margin of 1.56% and a return on equity of 1.48%. As a group, equities research analysts predict that Vericel Co. will post 0.13 earnings per share for the current year.

Analyst Upgrades and Downgrades

Several equities research analysts have recently issued reports on VCEL shares. Stephens upgraded Vericel to a “strong-buy” rating in a report on Monday, December 2nd. Truist Financial increased their price objective on shares of Vericel from $61.00 to $67.00 and gave the company a “buy” rating in a research report on Wednesday, December 18th. Canaccord Genuity Group reaffirmed a “buy” rating and set a $60.00 target price on shares of Vericel in a research report on Tuesday, November 19th. StockNews.com upgraded Vericel from a “sell” rating to a “hold” rating in a research note on Tuesday, December 24th. Finally, HC Wainwright reiterated a “buy” rating and set a $60.00 price objective on shares of Vericel in a research note on Friday, November 8th. One investment analyst has rated the stock with a hold rating, six have given a buy rating and one has issued a strong buy rating to the company’s stock. According to MarketBeat, the stock has a consensus rating of “Buy” and a consensus price target of $61.14.

Insider Activity at Vericel

In other Vericel news, Director Steven C. Gilman sold 5,833 shares of the business’s stock in a transaction dated Wednesday, October 2nd. The shares were sold at an average price of $40.35, for a total value of $235,361.55. Following the transaction, the director now directly owns 11,000 shares in the company, valued at $443,850. The trade was a 34.65 % decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at this hyperlink. Also, Director Paul K. Wotton sold 2,600 shares of the business’s stock in a transaction dated Wednesday, December 4th. The stock was sold at an average price of $58.72, for a total transaction of $152,672.00. Following the completion of the transaction, the director now directly owns 27,402 shares of the company’s stock, valued at approximately $1,609,045.44. This represents a 8.67 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Over the last ninety days, insiders sold 44,266 shares of company stock worth $2,090,636. 5.20% of the stock is owned by corporate insiders.

Vericel Profile

Vericel Corporation, a commercial-stage biopharmaceutical company, engages in the research, development, manufacture, and distribution of cellular therapies for sports medicine and severe burn care markets in North America. The company markets autologous cell therapy products comprising MACI, an autologous cultured chondrocytes on porcine collagen membrane for the repair of symptomatic, and single or multiple full-thickness cartilage defects of the knee; Epicel, a permanent skin replacement humanitarian use device for the treatment of adult and pediatric patients with deep-dermal or full-thickness burns; and NexoBrid, a biological orphan product for eschar removal in adults with deep partial-thickness and/or full-thickness thermal burns.